On October 15, Moderna, Inc. rose 3.05% in Regular Trading, trading at $223.17 per share, with turnover of $18.6 billion.

The move came as the market continued to digest strengthening commercialization expectations for personalized cancer vaccine intismeran autogene, while biotechnology peers also advanced, reinforcing sector sentiment.

Recent developments show Moderna, Inc. expanded its collaboration with Merck and Tempus to support the potential commercialization of intismeran autogene, including tumor tissue and blood sample handling, sequencing, and manufacturing support. In parallel, a public-private initiative involving the US National Institutes of Health to accelerate cancer vaccine development has continued to bolster expectations for the mRNA oncology platform. The latest gain also aligns with broader strength across large biotechnology names, including AbbVie, Amgen, Vertex Pharmaceuticals, Gilead Sciences, and Regeneron Pharmaceuticals.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)